Literature DB >> 16049686

[Salivary gland carcinomas. 1. Epidemiology, etiology, malignancy criteria, prognostic parameters and classification].

S Lang1, N Rotter, A Lorenzen, S Ihrler, R Eckel, D Hölzel, G Rasp, B Wollenberg, K Sommer.   

Abstract

Salivary gland carcinomas comprise a rare group of malignant tumors which are difficult to diagnose and treat due to their histopathologic diversity, variable clinical course and anatomic location, particularly with respect to the facial nerve. The present paper summarizes important features of these tumors, including recent advances in their management, i.e., diagnosis, surgery of the primary tumor, neck dissection, radiation therapy, and updates risk factors, criteria of malignancy, and prognostic variables, taking into account the relevant literature. Additionally, the present paper highlights briefly the survival rates of patients suffering from salivary gland carcinomas. The present overview is divided into two parts: the first is focused on epidemiology, etiology, criteria of malignancy, prognostic factors, and tumor classification, while part II discusses the diagnosis and therapy of salivary gland carcinomas.

Entities:  

Mesh:

Year:  2005        PMID: 16049686     DOI: 10.1007/s00106-005-1293-3

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  28 in total

1.  Prognosis of malignant tumors of the parotid gland with facial paralysis.

Authors:  J Conley; R C Hamaker
Journal:  Arch Otolaryngol       Date:  1975-01

2.  Molecular genetic alterations in carcinoma ex-pleomorphic adenoma: a putative progression model?

Authors:  A K El-Naggar; D Callender; M M Coombes; K Hurr; M A Luna; J G Batsakis
Journal:  Genes Chromosomes Cancer       Date:  2000-02       Impact factor: 5.006

3.  Prognostic index for patients with parotid carcinoma: external validation using the nationwide 1985-1994 Dutch Head and Neck Oncology Cooperative Group database.

Authors:  Vincent L M Vander Poorten; Augustinus A M Hart; Bernardus F A M van der Laan; Robert J Baatenburg de Jong; Johannes J Manni; Henri A M Marres; Cees A Meeuwis; Herman Lubsen; Chris H J Terhaard; Alfonsus J M Balm
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

4.  Carcinoma in pleomorphic adenoma of the parotid gland.

Authors:  C M Eneroth; C Blanck; P A Jakobsson
Journal:  Acta Otolaryngol       Date:  1968-12       Impact factor: 1.494

Review 5.  [Diagnosis and therapy of salivary gland tumors. I].

Authors:  R Chilla
Journal:  HNO       Date:  1995-10       Impact factor: 1.284

6.  Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness.

Authors:  S Sugano; K Mukai; H Tsuda; S Hirohashi; S Furuya; Y Shimosato; S Ebihara; I Takeyama
Journal:  Laryngoscope       Date:  1992-08       Impact factor: 3.325

7.  Malignant parotid tumors in 110 consecutive patients: treatment results and prognosis.

Authors:  D Pedersen; J Overgaard; H Søgaard; O Elbrønd; M Overgaard
Journal:  Laryngoscope       Date:  1992-09       Impact factor: 3.325

Review 8.  [Salivary gland tumors. Clinical aspects and therapy].

Authors:  H Swoboda; P Franz
Journal:  Radiologe       Date:  1994-05       Impact factor: 0.635

9.  Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy.

Authors:  J G Armstrong; L B Harrison; R H Spiro; D E Fass; E W Strong; Z Y Fuks
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1990-03

10.  Prognostic variables in parotid gland cancer.

Authors:  R A Frankenthaler; M A Luna; S S Lee; K K Ang; R M Byers; O M Guillamondegui; P Wolf; H Goepfert
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1991-11
View more
  1 in total

1.  [On the diagnosis and treatment of parotid gland tumors. Results of a nationwide survey of ENT hospitals in Germany].

Authors:  S F Preuss; O Guntinas-Lichius
Journal:  HNO       Date:  2006-11       Impact factor: 1.284

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.